526139 Stock Overview
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Transgene Biotek Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹7.95 |
| 52 Week High | ₹12.46 |
| 52 Week Low | ₹2.36 |
| Beta | 0.78 |
| 1 Month Change | -10.27% |
| 3 Month Change | -26.25% |
| 1 Year Change | 210.55% |
| 3 Year Change | 56.19% |
| 5 Year Change | 67.37% |
| Change since IPO | -95.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 526139 | IN Biotechs | IN Market | |
|---|---|---|---|
| 7D | -1.4% | -2.4% | -1.5% |
| 1Y | 210.5% | 13.4% | 45.0% |
Return vs Industry: 526139 exceeded the Indian Biotechs industry which returned 13.4% over the past year.
Return vs Market: 526139 exceeded the Indian Market which returned 45% over the past year.
Price Volatility
| 526139 volatility | |
|---|---|
| 526139 Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 526139's share price has been volatile over the past 3 months.
Volatility Over Time: 526139's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Koteswara Kanuru | www.transgenebiotek.com |
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers oncology drugs, oral drug delivery, and biogenerics, as well as HIV and multiple sclerosis drugs. The company provides TrabiDHA for use in health foods, baby food/formulas, health supplements, and chicken and animal feed; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption.
Transgene Biotek Limited Fundamentals Summary
| 526139 fundamental statistics | |
|---|---|
| Market cap | ₹602.37m |
| Earnings (TTM) | -₹18.62m |
| Revenue (TTM) | ₹1.90m |
317.2x
P/S Ratio-32.3x
P/E RatioIs 526139 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 526139 income statement (TTM) | |
|---|---|
| Revenue | ₹1.90m |
| Cost of Revenue | ₹737.52k |
| Gross Profit | ₹1.16m |
| Other Expenses | ₹19.78m |
| Earnings | -₹18.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 61.16% |
| Net Profit Margin | -980.65% |
| Debt/Equity Ratio | 122.2% |
How did 526139 perform over the long term?
See historical performance and comparison